×
PaxMedica Common Stock Net 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PaxMedica common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
PaxMedica Common Stock Net 2021-2024 | PXMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
PaxMedica common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$180.5B
Regeneron Pharmaceuticals (REGN)
$126.8B
Vertex Pharmaceuticals (VRTX)
$123.3B
Gilead Sciences (GILD)
$104.5B
Bristol Myers Squibb (BMY)
$99.4B
CSL (CSLLY)
$97.5B
GSK (GSK)
$86.3B
Alnylam Pharmaceuticals (ALNY)
$35.5B
Argenex SE (ARGX)
$32.1B
Biogen (BIIB)
$29.3B
BioNTech SE (BNTX)
$26.8B
Moderna (MRNA)
$26.1B
Illumina (ILMN)
$21.4B
BeiGene (BGNE)
$19.3B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.6B
Exact Sciences (EXAS)
$13.1B
Vaxcyte (PCVX)
$13.1B
Insmed (INSM)
$12.9B
Incyte (INCY)
$12.9B
Bio-Techne Corp (TECH)
$12.7B
Sarepta Therapeutics (SRPT)
$12.1B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Ascendis Pharma (ASND)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Exelixis (EXEL)
$7.7B